Experimental CAR-T therapy takes on relapsed blood cancers
NCT ID NCT07234045
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage study is testing a new treatment called CT1195E CAR-T cells in 30 adults with B-cell blood cancers that have come back or not responded to standard treatments. The therapy involves modifying a patient's own immune cells to better recognize and attack cancer cells. The main goals are to check the safety and find the right dose, while also looking at how well it works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CT1195E CAR-T cells (a type of immune cell therapy)
What this could lead to
If successful, this could point toward a new treatment option for patients with hard-to-treat B-cell blood cancers that have not responded to standard therapies.
What could go wrong
This is a very early Phase 1 trial with only 30 participants, so it is primarily testing safety and dosing. The therapy may not work well or could cause serious side effects, and it is far from being widely available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
China Institute of Hematology and Blood Diseases Hospital
Tianjin, Tianjin Municipality, 301617, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact